What are the ASH recommendations for treatment of resistant immune thrombocytopenic purpura (ITP) in children?

Updated: Apr 22, 2018
  • Author: Craig M Kessler, MD, MACP; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print
Answer

For second-line pharmacologic therapy, ASH suggests that rituximab or high-dose dexamethasone may be considered for children or adolescents with ITP who have significant ongoing bleeding despite treatment with IVIg, anti-D, or conventional doses of corticosteroids. Rituximab or high-dose dexamethasone may also be considered as an alternative to splenectomy in children and adolescents with chronic ITP or in patients who do not respond favorably to splenectomy.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!